{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115317","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.791784+00:00","generated_at":"2026-05-30T03:32:45.244932+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TELA Bio Q3 2024: revenue $19.0M (+26% YoY), net loss $10.4M; reaffirms FY2024 guidance","bullets":["Revenue $19.0M, +26% YoY; OviTex unit sales +39%, OviTex PRS +44% YoY.","Net loss $10.4M vs $11.0M loss in Q3 2023; operating loss $9.4M vs $10.2M.","Gross margin 68% vs 69% YoY due to higher excess/obsolete inventory charge.","Closed public offering yielding ~$46M gross proceeds; cash $17.3M at Sept 30.","Expects $5M-$10M reduction in 2025 operating expenses from H1 2024 annualized; reiterates FY2024 revenue guidance $74.5M-$76.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115317","json":"https://secwatch.observer/filing/0001104659-24-115317.json","markdown":"https://secwatch.observer/filing/0001104659-24-115317.md","text":"https://secwatch.observer/filing/0001104659-24-115317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924115317/0001104659-24-115317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924115317/tm2427737d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:32:45.244932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}